On November 13, 2026, Lifeward Ltd. announced its financial results for the third quarter ended September 30, 2026. The company reported a mixed performance, reflecting both challenges and strategic shifts as it transitions its ReWalk product distribution model. This update is significant for Lifeward as it navigates changes in its business strategy, which could impact its market position and growth potential.

Lifeward Ltd., a diversified biomedical innovation company, operates in the orthopedic, prosthetic, and surgical appliances and supplies sector (SIC: 3842). The company trades under the ticker LFWD on the Nasdaq exchange. Its recent filings include a Form 10-Q on November 13, 2026, and an 8-K on the same day, detailing its financial condition and operational results.

According to the SEC filing (accession number 0001178913-26-005208), Lifeward reported a total revenue of $5.4 million for Q3 2026, down from $6.2 million in the same quarter of 2025. The decline is attributed to a strategic shift in the distribution of its ReWalk Personal Exoskeleton, which saw revenue drop to $1.7 million from $3.0 million year-over-year. The company is transitioning from direct sales to a channel-partner model, which it believes will enhance patient access and support long-term revenue growth.

“The third quarter was a transitional quarter for Lifeward, marked by continued AlterG growth as we move into the advanced stages of transitioning ReWalk to a channel-partner distribution model,” said Josh Hexter, Interim Chief Executive Officer of Lifeward. He emphasized that while this shift might create short-term timing gaps in sales, the long-term benefits of partnering with established providers are expected to significantly expand access to ReWalk.

In terms of financial performance, revenue from AlterG products and services increased by 18% to $3.6 million, driven by higher U.S. unit shipments and improved average selling prices. Despite these gains, the overall gross margin for the company fell to 27.4%, down from 43.7% in the previous year. This decrease was primarily due to adverse foreign exchange fluctuations, increased freight costs, and expenses related to the acquisition of Oratech Pharmaceuticals Ltd.

The company's operating loss for the quarter was $6.0 million, compared to $3.1 million in Q3 2025. Net loss also widened to $5.1 million, or $1.32 per share, reflecting higher operating expenses and investment in clinical trials and product development.

Looking ahead, Lifeward is focused on expanding its partnerships to enhance the distribution of ReWalk. The company is also strengthening its reimbursement access, with ReWalk covered by Medicare and major Medicare Advantage insurers, which positions it to reach more eligible patients. Furthermore, Lifeward is advancing its development of AI-enabled rehabilitation technologies, aiming to integrate these innovations into its product offerings.

As Lifeward navigates these changes, it remains to be seen how competitors in the orthopedic and surgical appliance industry will respond to similar market dynamics. The company's strategic shift could serve as a case study for others in the sector, particularly those facing challenges in direct sales and distribution.

Details were not available in the SEC filing regarding future steps in Lifeward's strategy, but the company appears committed to its new distribution model and the expansion of its product offerings.